Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8415345 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(5 years from now) | |
US7994185 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jan, 2030
(5 years from now) | |
US8703781 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Oct, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8835443 | NOVARTIS | Pyrimidine compound and medical use thereof |
Jun, 2025
(1 year, 2 months from now) | |
US8835443 (Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(1 year, 8 months from now) | |
US9233956 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
May, 2029
(5 years from now) | |
US9233956 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Nov, 2029
(5 years from now) | |
US7994185 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(6 years from now) | |
US8415345 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(6 years from now) | |
US8952018 | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Oct, 2030
(6 years from now) | |
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(7 years from now) | |
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(7 years from now) | |
US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(9 years from now) | |
US11504333 | NOVARTIS | Pharmaceutical composition |
Jun, 2038
(14 years from now) | |
US11504333 (Pediatric) | NOVARTIS | Pharmaceutical composition |
Dec, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Mar 16, 2030 |
New Indication (I) | Jun 22, 2025 |
Pediatric Exclusivity (PED) | Dec 22, 2025 |
Market Authorisation Date: 29 May, 2013
Treatment: Tafinlar is indicated, in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic thera...
Dosage: CAPSULE;ORAL